Literature DB >> 16220213

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.

H Remschmidt1, P Hoare, C Ettrich, A Rothenberger, P Santosh, M Schmidt, Q Spender, R Tamhne, M Thompson, C Tinline, G E Trott, R Medori.   

Abstract

AIM: The aim of this study was to assess the impact of switching from immediate-release (IR) methylphenidate (MPH) to OROS MPH (CONCERTA, a once-daily long-acting MPH formulation, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
METHODS: Subjects with ADHD aged 6-16 (n=105),who were stably maintained on their current IR MPH regimen (10-60 mg/day), were switched to 18, 36 or 54 mg OROS MPH once daily for 21 days, depending on pre-study daily MPH dose. ADHD symptoms were assessed by parents, teachers and investigators.
RESULTS: By Day 21, parent/caregiver IOWA Conners ratings had decreased from baseline by 2.7 points to 5.2 (I/O), and by 1.8 points to 5.0 (O/D). Teacher IOWA Conners ratings were maintained. Decreases in IOWA Conners ratings are indicative of ADHD symptom improvement. Approximately 75% of parents and investigators rated therapy as good or excellent. OROS MPH therapy was well tolerated.
CONCLUSIONS: Switching from IR MPH to OROS MPH maintained and may have improved symptom control in children and adolescents with ADHD, during the course of this study. The changes in parent/caregiver IOWA Conners ratings suggest that OROS MPH improves symptom control in the after-school period. This is consistent with the 12-h duration of action previously demonstrated for OROS MPH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220213     DOI: 10.1007/s00787-005-0467-6

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  12 in total

Review 1.  Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Authors:  Laurence L Greenhill; Steven Pliszka; Mina K Dulcan; William Bernet; Valerie Arnold; Joseph Beitchman; R Scott Benson; Oscar Bukstein; Joan Kinlan; Jon McClellan; David Rue; Jon A Shaw; Saundra Stock
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-02       Impact factor: 8.829

2.  Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies.

Authors:  A Klassen; A Miller; P Raina; S K Lee; L Olsen
Journal:  Can J Psychiatry       Date:  1999-12       Impact factor: 4.356

3.  A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.

Authors:  W E Pelham; E M Gnagy; A M Chronis; L Burrows-MacLean; G A Fabiano; A N Onyango; D L Meichenbaum; A Williams; H R Aronoff; R L Steiner
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

4.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.

Authors:  L L Greenhill; J M Swanson; B Vitiello; M Davies; W Clevenger; M Wu; L E Arnold; H B Abikoff; O G Bukstein; C K Conners; G R Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J S March; J H Newcorn; J B Severe; K Wells; T Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

5.  Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Authors:  W E Pelham; E M Gnagy; L Burrows-Maclean; A Williams; G A Fabiano; S M Morrisey; A M Chronis; G L Forehand; C A Nguyen; M T Hoffman; T M Lock; K Fielbelkorn; E K Coles; C J Panahon; R L Steiner; D L Meichenbaum; A N Onyango; G D Morse
Journal:  Pediatrics       Date:  2001-06       Impact factor: 7.124

6.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Authors:  M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

7.  ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.

Authors:  Timothy Wilens; William Pelham; Mark Stein; C Keith Conners; Howard Abikoff; Marc Atkins; Gerald August; Laurence Greenhill; Keith McBurnett; Donna Palumbo; James Swanson; Mark Wolraich
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-04       Impact factor: 8.829

8.  Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.

Authors:  James Swanson; Suneel Gupta; Andrew Lam; Ira Shoulson; Marc Lerner; Nishit Modi; Elizabeth Lindemulder; Sharon Wigal
Journal:  Arch Gen Psychiatry       Date:  2003-02

Review 9.  Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement.

Authors:  James Swanson
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  The differential validity of teacher ratings of inattention/overactivity and aggression.

Authors:  M S Atkins; W E Pelham; M H Licht
Journal:  J Abnorm Child Psychol       Date:  1989-08
View more
  18 in total

1.  Child attention deficit hyperactive disorder co morbidities on family stress: effect of medication.

Authors:  Desiree Silva; Stephen Houghton; Erika Hagemann; Peter Jacoby; Brad Jongeling; Carol Bower
Journal:  Community Ment Health J       Date:  2014-08-26

2.  Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea.

Authors:  Bung-Nyun Kim; Ye-Ni Kim; Un-Sun Cheong; Jae-Won Kim; Jun-Won Hwang; Min-Sup Shin; Soo-Churl Cho
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

Review 3.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

4.  Using the ASEBA to Screen for Callous Unemotional Traits in Early Childhood: Factor Structure, Temporal Stability, and Utility.

Authors:  Michael T Willoughby; Daniel A Waschbusch; Ginger A Moore; Cathi B Propper
Journal:  J Psychopathol Behav Assess       Date:  2011-03

5.  An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.

Authors:  Manfred Döpfner; Anja Görtz-Dorten; Dieter Breuer; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

6.  An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.

Authors:  Manfred Döpfner; Dieter Breuer; Daniel Walter; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

7.  12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.

Authors:  Peter Hoare; H Remschmidt; R Medori; C Ettrich; A Rothenberger; P Santosh; M Schmit; Q Spender; R Tamhne; M Thompson; C Tinline; G E Trott
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-09       Impact factor: 4.785

8.  Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.

Authors:  Carlos Renato Moreira Maia; Breno Córdova Matte; Henrique Tschoepke Ludwig; Luis Augusto Rohde
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-04       Impact factor: 4.785

9.  An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence.

Authors:  Aribert Rothenberger; Andreas Becker; Dieter Breuer; Manfred Döpfner
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

Review 10.  Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.

Authors:  Jan Buitelaar; Rossella Medori
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-10-13       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.